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Abstract
Background: The immunohistochemical detection of estrogen (ER) and progesterone (PR) receptors in breast
cancer is routinely used for prognostic and predictive testing. Whole slide digitalization supported by dedicated
software tools allows quantization of the image objects (e.g. cell membrane, nuclei) and an unbiased analysis of
immunostaining results. Validation studies of image analysis applications for the detection of ER and PR in breast
cancer specimens provided strong concordance between the pathologist’s manual assessment of slides and
scoring performed using different software applications.
Methods: The effectiveness of two connected semi-automated image analysis software (NuclearQuant v. 1.13
application for Pannoramic™ Viewer v. 1.14) for determination of ER and PR status in formalin-fixed paraffin
embedded breast cancer specimens immunostained with the automated Leica Bond Max system was studied. First
the detection algorithm was calibrated to the scores provided an independent assessors (pathologist), using
selected areas from 38 small digital slides (created from 16 cases) containing a mean number of 195 cells. Each cell
was manually marked and scored according to the Allred-system combining frequency and intensity scores. The
performance of the calibrated algorithm was tested on 16 cases (14 invasive ductal carcinoma, 2 invasive lobular
carcinoma) against the pathologist’s manual scoring of digital slides.
Results: The detection was calibrated to 87 percent object detection agreement and almost perfect Total Score
agreement (Cohen’s kappa 0.859, quadratic weighted kappa 0.986) from slight or moderate agreement at the start of
the study, using the un-calibrated algorithm. The performance of the application was tested against the pathologist’s
manual scoring of digital slides on 53 regions of interest of 16 ER and PR slides covering all positivity ranges, and the
quadratic weighted kappa provided almost perfect agreement ( = 0.981) among the two scoring schemes.
Conclusions: NuclearQuant v. 1.13 application for Pannoramic™ Viewer v. 1.14 software application proved to be a
reliable image analysis tool for pathologists testing ER and PR status in breast cancer.
Background
Early detection of breast cancer, one of the important
causes of cancer morbidity worldwide [1], can signifi-
cantly improve the survival probability of the patients
[2,3]. Identifying molecules which regulate the growth of
normal and transformed breast epithelium by means of
immunohistochemistry, has been used as adjuncts for
diagnostic, prognostic, and predictive decision-making
[4]. The most established validated molecular markers
predicting responsiveness of patients for molecular tar-
geted therapy are estrogen (ER) and progesterone (PR)
receptors [5] and the type-2 human epidermal growth
factor receptor (HER2).
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patients with double positive (ER/PR) status are likely to
benefit from endocrine/hormonal therapy. According to
the recent ASCO-CAP guidelines, ER and PR status
should be determined in all invasive breast cancers and
recurrences [6]. However, the reliability of assay results
depends on both the reproducibility of assay perfor-
mance and its interpretation [7,8].
Standardized protocols used by automated immunos-
tainers set up high standards in test reproducibility.
Whole slide digitalization, supported by dedicated soft-
ware tools allows image object quantization based on
colour and intensity segmentation for unbiased analysis
of immunostaining results [9].
Several validation studies of image analysis applica-
tions for the detection of ER and PR in breast cancer
specimens have been published [10-16] and results pro-
vided strong concordance between the pathologist’s
manual assessment of slides and scoring performed by
the different software applications.
Our survey was performed to test the effectiveness of
two connected software application: Pannoramic™
Viewer v. 1.14 (hereinafter PV) and NuclearQuant appli-
cation for PV v. 1.13 (hereinafter NQ)b o t hm a n u f a c -
tured by 3DHISTECH Ltd. (Budapest, Hungary). PV
enables the visualization of digital slides, users being
able to inspect and annotate (i.e. select certain regions
of an image) digital slides. These editable (i.e. possibility
for deletion, rename) annotations can be rectangular
and/or free hand. NQ is an image-analysis software con-
nected to PV, suitable for unbiased automated analysis
of digital image objects based on colour, intensity and
size. It detects and separates nuclei-shaped connected
pixel sets (e.g. immunolabelled cell nuclei) on micro-
scopic digital slides (*.mrxs file format) created using
one of the digital slide scanners manufactured by
3DHISTECH Ltd. (i.e. Pannoramic DESK, Pannoramic
MIDI, Pannoramic SCAN 150). For image standardiza-
tion [17] Wallis image filters are used, to compensate
rarely perceptible but possibly occurring local intensity
deviations arising from unsuitable luminance and optical
aberrations. NQ uses a “colour deconvolution” algorithm
for the scoring process, which decomposes the RGB
image into greyscale intensity images that represent the
staining or dye concentration maps individually for each
stain. Nuclei scoring is based on the intensity of con-
nected pixel sets measured on the 3,3’-Diaminobenzi-
dine (DAB) intensity image only. The nuclei detection is
performed on the intensity normalized greyscale image,
based on the morphometrical parameters, such as opti-
mal roundness, average density and proper contrast of
the intensity at the boundary. Scores are calculated for
each detected object, based on the average intensity of
the corresponding pixels of the intensity image. Users
may filter object by size or shape, and can separate joint
objects. The information necessary for the algorithm to
be used is not saved on the image itself but are stored
in Microscopic Image Segmentation Profile files
(*.misp). The application can be run on whole slides or
annotations, and the detected objects can be viewed,
reclassified, relocated and visualized. Both research use
applications are intended to support in vitro diagnostic
decision-making, aiding pathologists in the detection,
scoring, classification and counting of cells of interests.
The aims of our validation study were: 1) calibration
of the algorithm for ER and PR detection built-in NQ
on immunostained slides after whole-slide digitalization;
and 2) assessment of equivalence of the semi-automated
detection using the software application with the manual
scoring of digital slides.
Methods
Samples, slide selection, digitalization and
pre-quantization procedures
ER and PR stained IHC breast cancer slides from 16
cases (14 invasive ductal carcinoma Grade I-III and 2
invasive lobular carcinoma) were used from the archive
of the 1st Department of Pathology and Experimental
Cancer Research of the Semmelweis University, Buda-
pest, Hungary. The formalin-fixed paraffin embedded
specimens were stained (as defined in the manufac-
turer’s staining protocol) on a Bond-max™ fully auto-
mated staining system (Leica Microsystems GmbH,
Germany), using Leica Microsystem’sm o u s em o n o c l o -
nal antibodies for ER (clone 6F11) and PR (clone 1A6).
Samples were selected to cover all positivity ranges,
selection based on the original diagnosis. Slides were
digitalized using a Pannoramic SCAN digital slide
scanner with Zeiss plan-apochromat objective (magnifi-
cation: 20×, Numerical aperture: 0,8) and Hitachi
(HV-F22CL) 3CCD progressive scan colour camera
(resolution: 0,2325 μm/pixel).
Detection calibration
The algorithm developed by the University of Pannonia,
Faculty of Information Technology, Veszprém, Hungary
had default detection parameters, defined based on a
training sample set (i.e. 68 hematoxilin, ER, PR, Ki67,
p53, p16 stained samples). The measurement of the
exact deviation in the object detection and scoring qual-
ity of the system was performed in a factual environ-
ment. The system needed to be calibrated for suitable
detection of ER and PR stained slides. During the cali-
bration the detection algorithm had to set to the optical
features of the digital slides created using the digital
slide scanners manufactured by 3DHISTECH Ltd.
The calibration was performed on a selected slide set.
Small areas (2-4/slide) representing each case were
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(n = 38) contained a mean number of 195 cells (min.
73- max. 489 cells). The pathologist scored each annota-
tion on the digital slides using PV. The slides were later
analyzed with NQ to compare the scores with those pro-
vided by the pathologist. The selection was followed by
a manual marking (i.e. encircling using the freehand
annotation option in PV) of each cell in the respective
annotation. Different colours were used to denote the
positivity classes (Figure 1). Pathologist reviewed the
suitability of the marking. The process was followed by
iterative analysis of each slide accompanied by the
adjustment of the detection parameters of NQ until
close reproduction of the manual encircling was
obtained. The separate *.misp files, created for each
slide after the most optimal detection setup, were ana-
lyzed with respect to the detection parameters (e.g.
object detection, correctness of cell marking) to obtain
the most appropriate setup and to create a main *.misp
file that can be used on any ER or PR stained slide.
After the optimal setup, all slides were re-analyzed using
NQ and the scores were compared with those provided
by the pathologist.
Equivalence assessment
One pathologist marked from 3 to 5 biologically repre-
sentative areas (regions of interest, ROI) on each digital
slide, and scored the ROI on a computer monitor using
PV only. The same ROI were later scored using NQ and
the results of the two scorings were compared. The
mean number of cells analyzed per slide was 5069 (min.
2,780-max. 19,740). The Allred scoring [18] was used by
the pathologists to score the slides, and the same scor-
ing was incorporated into NQ. This widely accepted and
used [19,20] semi-quantitative scoring system takes into
account the percent of the positively stained tumour
cells and the staining intensity of the cells. The percent
of positively stained tumour cells represent the Positivity
Score, ranging from 0 to 5 (i.e 0 = no stained cell, 1 =
1/100 stained cells, 2 = 1/10 stained cells, 3 = 1/3
stained cells, 4 = 2/3 stained cells, 5 = up to 100%
stained cells). The staining intensity, defined as the
Intensity Score, ranges from 0 (i.e. no staining) to 3
(i.e. strong staining). The two scores are added to obtain
the Total Score that ranges from 0 to 8, and represents
positive tumours if equals or exceeds 3 [18].
Statistics
Agreement between the pathologist’s scores of digital
slides and scores obtained using NQ was analyzed using
Cohen’s kappa. The strength of agreement of the kappa
statistic was interpreted using the classes proposed by
Landis and Koch [21] as follows: <0.00 = poor agree-
ment, 0.00-0.20 = slight agreement, 0.21-0.40 = fair
agreement, 0.41-0.60 = moderate agreement, 0.61-0.80 =
substantial agreement, 0.81-1.00 = almost perfect agree-
ment. The strength of the agreement was additionally
assessed using the Spearman rank-correlation coeffi-
cient. In order to test the clinical relevancy of the agree-
ment, quadratic weighted kappa was calculated as well,
by assigning the weight 0 for the most relevant disagree-
ment (i.e. negative Total Score = 0, 1 or 2 vs. highly
positive Total Score). The data were analyzed using the
SPSS 17.0 for Windows (SPSS Inc., Chicago, USA) and
MedCalc for Windows v. 11.2.1.0 (MedCalc Software,
Mariakerke, Belgium) software applications.
Results
Detection calibration
The first step of the testing was the assessment of the
object detection and scoring quality of the newly devel-
oped algorithm in NQ, without calibration. The mea-
surement of the deviation in the object detection and
scoring of the algorithm was performed to test for the
need of calibration. The analysis of the slides provided
slight agreement between the two scores if tested with
Cohen’s kappa ( = 0.138, SE = 0.0815, 95%CI =
-0.0217-0.298), and moderate agreement using quadratic
weighted kappa ( = 0.485, SE = 0.100). Result showed
that the object detection and scoring of the algorithm
was not adequate, and therefore needed to be calibrated.
Our approach using encircled cell nuclei (Figure 1)
proved to be an adequate input to calibrate the optimal
object detection and positivity determination of the
algorithm (Figure 2).
The calibrated algorithm provided an overall 87%
agreement in cell detection with the manual marking,
which proves a correct object detection mechanism
(Figure 3). Results provided with the main *.misp file
were tested against the scores provided by the patholo-
gist. The application, similar to the pathologist, rated
eight annotations as negative and 30 as positive. Almost
Figure 1 Manual marking of cells within a ROI. Blue = negative
cells, Red = positive cells.
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with Cohen’sk a p p a(  = 0.859, SE = 0.0666, 95% CI =
0.729-0.990), and quadratic weighted kappa ( =0 . 9 8 6 ,
SE = 0.162). There was a significant correlation between
the pathologist’ss c o r e sa n dt h eo n e sp r o v i d e db yNQ
(Spearman’s rho = 0.953, df = 37, p < 0.0001, 95% CI
for rho 0.911-0.976).
Equivalence assessment
Two slides containing 3-3 annotations each have been
removed from the analysis. Both contained necrotized
and ragged tissue sections, and additionally relatively
intense cytoplasmic staining, thus these were not suita-
ble for quantization using the software application.
Altogether 53 annotations have been used in the ana-
lysis. Seven annotations weres c o r e db yt h ep a t h o l o g i s t
as negative (i.e. Total Score between 0 and 2), 46 as
positive, and the same results were obtained using NQ.
Four discrepancies were recorded between the Positivity
Scores provided by pathologist and the application.
Three included down-scoring (i.e. lower NQ positivity
score) and in one case up scoring (i.e. PS = 0 vs. 1).
Similar results were obtained in the Intensity Score.
Cohen’s kappa showed substantial agreement ( =
0.795, SE = 0.0669, 95%CI = 0.664-0.926), whereas
quadratic weighted kappa almost perfect agreement ( =
0.981, SE = 0.137). There was a significant correlation
Figure 2 Agreement in cell detection between the un-calibrated and calibrated algorithm and the manual encircling.
Figure 3 Object detection of the calibrated NuclearQuant
algorithm. Blue = negative cells, Red = positive cells.
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by NQ (Spearman’s rho = 0.975, df = 52, p < 0.0001,
95% CI for rho 0.958-0.986).
Discussion
Pathologist usually score IHC-stained slides with the light
microscope by semi-quantitative methods, which are not
standardized. Although there are several scoring guides
available with colourful pictures of various slides depict-
ing different positivity, biological samples are more het-
erogeneous and more ‘awkward’ slides exists, which are
hard to be categorized. These are mainly cases with low
or moderate positivity and with vesicular nuclear struc-
ture, where the chromatin is associated to the nuclear
membrane and therefore the immunstaining is hard to
capture. Usually a simple scoring takes several seconds,
but in these problematic cases, it may take even minutes
and may be un-reproducible since the result depends
merely on the training and the tiredness of the patholo-
gists’ eyes and the time the pathologist deals with a single
slide. By using a well calibrated and optimized automatic
scoring algorithm and software, these risky cases could
be scored in a standardized and reproducible way, and
could additionally be documented thoroughly.
The calibration procedure applied using encircled
nuclei proved an adequate input for the adjustment of
the optimal object detection and the intensity thresholds
to the score definition in our software application. The
overall 87% cell detection agreement is regarded as
excellent, considering that the slides analyzed covered
the entire positivity range. This method could be used
to suitably calibrate similar image analysis applications.
Following the calibration of the NQ algorithm the
agreement with the scores provided by the pathologist
was almost perfect ( = 0.981). Similar results were
reported in the literature following the assessment of
different image analysis applications. Sharangpani et al.
[15] found an agreement of 85% and 81% between the
automatic determination of positivity/negativity of ER
and PR stained cells with the subjective measurements.
The agreement rate of the automated and manual scor-
ing using higher number of samples then the ones used
in our validation survey was reported to be 0.78 for ER
and 0.72 for PR [10], 0.84 for ER [12] or 0.918 for ER
[16]. Gokhale et al. [14] reported 95% concordance
between the automated systems and observers, and
Mofidi et al. [11] a highly significant correlation (r
2 =
0.844) between the digital scores and the manual ones.
Although the semi-automated assessment has several
advantages over the manual scoring, the process has its
drawbacks as well, that include i) precise and more time
consuming selection of ROI to be investigated, as stro-
m a lt i s s u em a yi n f l u e n c et h eT o t a lS c o r eg i v e nb yt h e
application, or ii) only well prepared specimens may be
quantified, as the detection algorithm may provide erro-
neous results if intense cytoplasmic staining is present
or when the nuclei are vesicular. Still these drawbacks
are superable by means of intensive training of patholo-
gists on the use of the analysis application. The occa-
sional misclassification errors, non-conceptional errors,
arising from poorly stained samples or samples of bad
quality can be solved during the review of the results by
the pathologist. NQ provides the user with the ability to
reclassify or drop individual detected objects, and thus
to censor the software provided results.
By use of image analysis applications such as NQ pre-
sented above, the quantization of nuclear markers could
be improved, made objective and reproducible. Further
large clinical performance evaluation study(ies) involving
several institutions and pathologists are needed to assess
the safety and effectiveness of this software application
with certainty before its initiation in the day-to-day
pathological workflow.
Conclusions
In conclusion, our data support the suitability of NQ to
reliably test ER and PR status in breast cancer. The cali-
bration procedure applied using encircled nuclei is an
adequate method to calibrate image analysis applica-
tions. Further large clinical performance evaluation stu-
dies should be performed to further characterize the
software application and prove its diagnostic validity.
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